326 related articles for article (PubMed ID: 29564490)
1. Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience.
Ceccon G; Lazaridis L; Stoffels G; Rapp M; Weber M; Blau T; Lohmann P; Kebir S; Herrmann K; Fink GR; Langen KJ; Glas M; Galldiks N
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1626-1635. PubMed ID: 29564490
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
Bashir A; Brennum J; Broholm H; Law I
J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
[TBL] [Abstract][Full Text] [Related]
4. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
6. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
[TBL] [Abstract][Full Text] [Related]
7. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
[TBL] [Abstract][Full Text] [Related]
8. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
9. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.
Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ
J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047
[TBL] [Abstract][Full Text] [Related]
10. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI.
Werner JM; Stoffels G; Lichtenstein T; Borggrefe J; Lohmann P; Ceccon G; Shah NJ; Fink GR; Langen KJ; Kabbasch C; Galldiks N
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1889-1901. PubMed ID: 31203420
[TBL] [Abstract][Full Text] [Related]
12. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
Tscherpel C; Dunkl V; Ceccon G; Stoffels G; Judov N; Rapp M; Meyer PT; Kops ER; Ermert J; Fink GR; Shah NJ; Langen KJ; Galldiks N
Neuro Oncol; 2017 May; 19(5):710-718. PubMed ID: 28039366
[TBL] [Abstract][Full Text] [Related]
13.
Suchorska B; Unterrainer M; Biczok A; Sosnova M; Forbrig R; Bartenstein P; Tonn JC; Albert NL; Kreth FW
J Neurooncol; 2018 Sep; 139(3):721-730. PubMed ID: 29948765
[TBL] [Abstract][Full Text] [Related]
14. Potential for differentiation of glioma recurrence from radionecrosis using integrated
Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
[TBL] [Abstract][Full Text] [Related]
15. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
Mehrkens JH; Pöpperl G; Rachinger W; Herms J; Seelos K; Tatsch K; Tonn JC; Kreth FW
J Neurooncol; 2008 May; 88(1):27-35. PubMed ID: 18217207
[TBL] [Abstract][Full Text] [Related]
16. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
[TBL] [Abstract][Full Text] [Related]
17. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
18. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.
Lohmann P; Stavrinou P; Lipke K; Bauer EK; Ceccon G; Werner JM; Neumaier B; Fink GR; Shah NJ; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):591-602. PubMed ID: 30327856
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Dynamic O-(2-[
Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
[TBL] [Abstract][Full Text] [Related]
20. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]